Shares of Humacyte, Inc. (HUMA) soared over 10% in pre-market trading on Thursday, following positive analyst ratings from two Wall Street firms.
TD Cowen analyst Josh Jennings reiterated a "Buy" rating on HUMA and set a price target of $10.00. Meanwhile, Piper Sandler analyst Allison Bratzel maintained a "Hold" rating but raised the firm's price target to $6.00.
The analyst ratings suggest a positive sentiment towards Humacyte's prospects, driving investor optimism and contributing to the pre-market surge in the company's stock price.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.